VectorY have been selected as winners of the Merck Millipore 2021 European Advance Biotech Program!

Written By BRONS + TEN KATE

The Merck Millipore Advance Biotech Grant Program helps biotech startups to develop and advance the next generation of drugs to market. We look forward to accelerating the development and manufacture of next-generation gene therapies in collaboration with the Merck Millipore team!

BRONS + TEN KATE https://www.bronstenkate.com
Previous

VectorY presents at ASGCT 2021 about advances and challenges of vectorized antibodies for the treatment of neuromuscular diseases.
Next

Launch of novel gene therapy company, VectorY, to develop innovative vectorized antibodies